News & Trends

• 17 2025-04

  Salubris' PCSK9 base-editing drug YOLT-101 ha...
• 14 2025-02

  SAL0140 Clinical Trial Application Accepted by NMP...
• 20 2025-01

  Announcement of the Positive Interim Data from the...
• 28 2024-11

  Salubris’innovative drugs Xinliting and FoLitan ® ...
• 27 2024-08

  Salubris obtaining the exclusive right of base edi...